Literature DB >> 17067352

Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study.

Raymond F Anton1, Marston Youngblood.   

Abstract

BACKGROUND: Carbohydrate-deficient transferrin (CDT) occurs as a higher percentage of normal transferrin (%CDT) in heavy drinkers. %CDT is used as a marker of both alcohol use disorder severity and treatment outcome both clinically and in treatment trials. Nevertheless, little is known about the parameters that predict which patients are %CDT positives at treatment entry. These parameters might include level of drinking, days of abstinence before testing, and severity of alcohol dependence before evaluation.
METHODS: %CDT levels were collected before randomization from participants of the COMBINE Study, a large federally sponsored multisite clinical trial evaluating medications and behavioral therapies in alcohol-dependent outpatients. %CDT (assayed in a central laboratory) was available in 1,193 individuals for whom drinking history in the 30 days before testing and measures of alcoholism severity were documented. The effects of drinking history and alcohol severity were evaluated for prediction of a %CDT-positive test status.
RESULTS: Less percent days abstinent (PDA) and more drinks per drinking day (DDD) were predictive of higher rates of %CDT-positive patients (maximum 67%). Up to 14 days of continuous abstinence before testing did not appear to significantly affect %CDT status. Rates of %CDT positives remained reasonably steady up to about 40% PDA. Years of drinking at dependence levels had an unexpected negative impact on %CDT-positive rates while previous treatment had a small but positive impact of %CDT-positive rates. ADS and DrInC scores had no predictive value over and above recent drinking amounts on %CDT status.
CONCLUSIONS: %CDT is more likely to be positive in those who have more days of drinking and to a lesser degree in those who drink more per drinking day. It can remain positive even in those alcoholic subjects who stop drinking many days before testing. Alcoholic subjects with more treatment experiences appear to have a marginally higher %CDT-positive rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067352     DOI: 10.1111/j.1530-0277.2006.00225.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  8 in total

1.  Clinical (nonforensic) application of ethyl glucuronide measurement: are we ready?

Authors:  Peter Jatlow; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

2.  Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2018-11-05       Impact factor: 3.455

3.  Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.

Authors:  Raymond F Anton; Patricia K Latham; Konstantin E Voronin; Patrick K Randall; Sarah W Book; Michaela Hoffman; Joseph P Schacht
Journal:  Alcohol Clin Exp Res       Date:  2018-02-12       Impact factor: 3.455

4.  Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?

Authors:  Dorian Hunter-Reel; Katie Witkiewitz; Allen Zweben
Journal:  Alcohol Clin Exp Res       Date:  2012-02-10       Impact factor: 3.455

5.  The validity of phosphatidylethanol in dried blood spots of newborns for the identification of prenatal alcohol exposure.

Authors:  Ludmila N Bakhireva; Lawrence Leeman; Renate D Savich; Sandra Cano; Hilda Gutierrez; Daniel D Savage; William F Rayburn
Journal:  Alcohol Clin Exp Res       Date:  2014-02-11       Impact factor: 3.455

6.  Ethylglucuronide in maternal hair as a biomarker of prenatal alcohol exposure.

Authors:  Hilda L Gutierrez; Lauren Hund; Shikhar Shrestha; William F Rayburn; Lawrence Leeman; Daniel D Savage; Ludmila N Bakhireva
Journal:  Alcohol       Date:  2015-07-21       Impact factor: 2.405

7.  Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

Authors:  Raymond F Anton; Konstantin E Voronin; Sarah W Book; Patricia K Latham; Patrick K Randall; Willam Bailey Glen; Michaela Hoffman; Joseph P Schacht
Journal:  Alcohol Clin Exp Res       Date:  2020-09-19       Impact factor: 3.455

8.  Ethyl glucuronide in hair: A 5-year retrospective cohort study in subjects sanctioned for driving under the influence of alcohol and psychoactive substances.

Authors:  Francesca Freni; Matteo Moretti; Sara Scardo; Claudia Carelli; Claudia Vignali; Maria Cristina Monti; Luca Morini
Journal:  Drug Test Anal       Date:  2022-04-05       Impact factor: 3.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.